Progenics Pharmaceuticals (PGNX) AZEDRA Revenues Likely to Start in 2Q, Needham & Company Says; PT to $10
Tweet Send to a Friend
Needham & Company analyst Chad Messer lowered the price target on Progenics Pharmaceuticals (NASDAQ: PGNX) to $10.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
